CAM
VIRX

ClariVest Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

ClariVest Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-238
Closed – – 777
2023
Q1 		$0 Hold
238
– – ﹤0.01% 783
2022
Q4 		$0 Hold
238
– – ﹤0.01% 755
2022
Q3 		$1K Sell
238
-134
-36% -$567 ﹤0.01% 667
2022
Q2 		$1K Hold
372
– – ﹤0.01% 676
2022
Q1 		$2K Buy
+372
New +$1.12K ﹤0.01% 608

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

ClariVest Asset Management's VIRX Position: Q2 2023 in Review

ClariVest Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2023, closing a stake of 238 shares.

ClariVest Asset Management first reported a position in VIRX in Q1 2022 and held it in 5 quarters. The position peaked at $2K in Q1 2022. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2023.

  • ClariVest Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • ClariVest Asset Management sold 238 Viracta Therapeutics, Inc. Common Stock shares in Q2 2023.
  • ClariVest Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
  • ClariVest Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $2K in Q1 2022.
  • 41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2023.

Based on ClariVest Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.